Login to Your Account


Lemtrada Cuts Relapse Rate, Brain Atrophy; BG-12 Data Also Wow

By Jennifer Boggs

Monday, October 24, 2011
Optimism could be building for Sanofi SA's Lemtrada (alemtuzumab), the drug at the center of negotiations surrounding the big pharma's acquisition of Genzyme Corp. earlier this year, following the release of detailed data from the first pivotal trial in relapsing-remitting multiple sclerosis (MS) patients that boosts positive top-line results reported in July.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription